Paper17567869
Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study.
Isaacs KL and 10 others. Inflamm Bowel Dis, 2007. Cited by 90 papers, by iCite.
Cite this record
ConductScience Library. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Papers, record 17567869. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17567869
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Infective Agents | Major topic |
| Pouchitis | Major topic |
| Rifamycins | Major topic |
| Acute Disease | |
| Administration, Oral | |
| Adult | |
| Chronic Disease | |
| Dose-Response Relationship, Drug | |
| Double-Blind Method | |
| Endoscopy, Gastrointestinal | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Male | |
| Pilot Projects | |
| Remission Induction | |
| Retrospective Studies | |
| Rifaximin | |
| Severity of Illness Index | |
| Treatment Outcome |
Source PubMed
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT06312683 | Rifaximin for the Secondary Prevention of Recurrent Pouchitis | Background | ClinicalTrials.gov | |
| NCT06864403 | Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch | Background | ClinicalTrials.gov | |
| NCT07756359 | Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008) | Background | ClinicalTrials.gov |
Cited by43
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 90 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42739016 | The Gut Microbiome in Pouchitis: A Narrative Review of Pathogenesis and Therapeutic Modulation. | Nutrients | 2026 | https://conductscience.org/library/papers/42739016 | PubMed |
| 41884160 | Optimal Antibiotic Selection for the Treatment of Pouchitis After Ileal Pouch-Anal Anastomosis. | J Inflamm Res | 2026 | https://conductscience.org/library/papers/41884160 | PubMed |
| 40515946 | Managing Pouchitis: Where do Antibiotics End, and Advanced Therapies Begin? | Curr Gastroenterol Rep | 2025 | https://conductscience.org/library/papers/40515946 | PubMed |
| 39948209 | A rifamycin SV in situ gelling formulation for the treatment of pouchitis. | Drug Deliv Transl Res | 2025 | https://conductscience.org/library/papers/39948209 | PubMed |
| 39466277 | Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders-A Systematic Review and Meta-Analysis. | Am J Gastroenterol | 2025 | https://conductscience.org/library/papers/39466277 | PubMed |
| 39334930 | Are Small Molecules Effective in Treating Inflammatory Pouch Disorders Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis? Here Is Where We Stand. | Biomolecules | 2024 | https://conductscience.org/library/papers/39334930 | PubMed |
| 38929596 | Diagnosis and Medical Treatment of Acute and Chronic Idiopathic Pouchitis in Inflammatory Bowel Disease. | Medicina (Kaunas) | 2024 | https://conductscience.org/library/papers/38929596 | PubMed |
| 38664536 | Pouchitis: pathophysiology and management. | Nat Rev Gastroenterol Hepatol | 2024 | https://conductscience.org/library/papers/38664536 | PubMed |
| 38128971 | AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders. | Gastroenterology | 2024 | https://conductscience.org/library/papers/38128971 | PubMed |
| 37971270 | The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review. | Clin Microbiol Rev | 2023 | https://conductscience.org/library/papers/37971270 | PubMed |
| 37815701 | A Systematic Review and Meta-analysis of Randomized Clinical Trials on the Prevention and Treatment of Pouchitis after Ileoanal Pouch Anastomosis. | J Gastrointest Surg | 2023 | https://conductscience.org/library/papers/37815701 | PubMed |
| 37007752 | Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. | Prz Gastroenterol | 2023 | https://conductscience.org/library/papers/37007752 | PubMed |
| 36777755 | #MondayNightIBD: Management of Chronic #Pouchitis. | Crohns Colitis 360 | 2020 | https://conductscience.org/library/papers/36777755 | PubMed |
| 36171809 | Acute pouchitis: the condition that time forgot about. | Ther Adv Gastroenterol | 2022 | https://conductscience.org/library/papers/36171809 | PubMed |
| 34868349 | α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis. | Ther Adv Gastroenterol | 2021 | https://conductscience.org/library/papers/34868349 | PubMed |
| 34335051 | Pouchitis: Clinical Features, Diagnosis, and Treatment. | Int J Gen Med | 2021 | https://conductscience.org/library/papers/34335051 | PubMed |
| 34249146 | Medical treatment of pouchitis: a guide for the clinician. | Ther Adv Gastroenterol | 2021 | https://conductscience.org/library/papers/34249146 | PubMed |
| 34180986 | Disease Activity Indices for Pouchitis: A Systematic Review. | Inflamm Bowel Dis | 2022 | https://conductscience.org/library/papers/34180986 | PubMed |
| 34163205 | Chronic Antibiotic-Refractory Pouchitis: Management Challenges. | Clin Exp Gastroenterol | 2021 | https://conductscience.org/library/papers/34163205 | PubMed |
| 33162735 | Inflammatory bowel disease and pregnancy: fertility, complications and treatment. | Ann Gastroenterol | 2020 | https://conductscience.org/library/papers/33162735 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17567869
GET https://conductscience.org/api/papers/v1/17567869/cited_by?page=2